<SEC-DOCUMENT>0001062822-22-000002.txt : 20220228
<SEC-HEADER>0001062822-22-000002.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228061715
ACCESSION NUMBER:		0001062822-22-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220228
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		22683799

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20220228.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:273b90fe-be65-4551-950d-6c0cc4735d9f,g:6d12946c-48d0-402f-a3e8-a90b7decbbc7,d:86120acddb484cb5af4c2c93815fd32e--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20220228</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV80L2ZyYWc6ZDAxZTExMDk3YmEyNDZmYTg2ZTlhYzMyN2UzZThiOGEvdGFibGU6OThmMzU5YWM5NmIyNDMwNmJlZjRkMzRkZjZkZGFjNzEvdGFibGVyYW5nZTo5OGYzNTlhYzk2YjI0MzA2YmVmNGQzNGRmNmRkYWM3MV8wLTEtMS0xLTIyNjY0_4d263885-649a-45a5-b385-6ddc6673d1f9">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV80L2ZyYWc6ZDAxZTExMDk3YmEyNDZmYTg2ZTlhYzMyN2UzZThiOGEvdGFibGU6OThmMzU5YWM5NmIyNDMwNmJlZjRkMzRkZjZkZGFjNzEvdGFibGVyYW5nZTo5OGYzNTlhYzk2YjI0MzA2YmVmNGQzNGRmNmRkYWM3MV8xLTEtMS0xLTIyNjY0_1455cc72-9b68-47a3-ad3e-f18d2bd140b6">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20220228.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i86120acddb484cb5af4c2c93815fd32e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc1_ad6cb52b-1c1a-4778-847a-18501610f667">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18yNjU_5542e1c1-5d92-45ab-893d-35e40be22ba5">February 28, 2022</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc2_2df0d953-5afc-4ec0-a27b-d131b0f67545">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Yjc4MmIxYzRlNmY1NGFiYzhkYTMzN2YxNGNhOWY1MDgvdGFibGVyYW5nZTpiNzgyYjFjNGU2ZjU0YWJjOGRhMzM3ZjE0Y2E5ZjUwOF8wLTAtMS0xLTIyNjY0_77e41f9a-4ebb-4bec-9b3a-1eb5f6b188b8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Yjc4MmIxYzRlNmY1NGFiYzhkYTMzN2YxNGNhOWY1MDgvdGFibGVyYW5nZTpiNzgyYjFjNGU2ZjU0YWJjOGRhMzM3ZjE0Y2E5ZjUwOF8wLTEtMS0xLTIyNjY0_136cc656-0649-4acf-9e55-7a9675ccd568">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Yjc4MmIxYzRlNmY1NGFiYzhkYTMzN2YxNGNhOWY1MDgvdGFibGVyYW5nZTpiNzgyYjFjNGU2ZjU0YWJjOGRhMzM3ZjE0Y2E5ZjUwOF8wLTItMS0xLTIyNjY0_bb01bf2d-4e62-4813-92d7-936581e1fc95">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc3_7372ef37-cb2d-44d7-9741-3608359d3dbe">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc0_c4a04b16-4d73-4648-abb4-5448da6a8219">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc5_f87e9e8b-1704-417d-9039-1663b96fa3a1">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y180MjA_1bdd8d6f-795d-4a8d-ad98-275a1f43eefd">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y180Nzk_7331dc80-7e09-4345-a9fd-0bfd5aaeea5b">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzgw_6a468c11-d390-457c-b19d-38a3520341ef">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Y2QzN2M0YjUyOTAyNGUzMzkxMTQ3MDU1MGIyMjJiNmUvdGFibGVyYW5nZTpjZDM3YzRiNTI5MDI0ZTMzOTExNDcwNTUwYjIyMmI2ZV8xLTAtMS0xLTIyNjY0_74ab4cde-9b3d-49f8-8aa3-fb7d36827b13">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Y2QzN2M0YjUyOTAyNGUzMzkxMTQ3MDU1MGIyMjJiNmUvdGFibGVyYW5nZTpjZDM3YzRiNTI5MDI0ZTMzOTExNDcwNTUwYjIyMmI2ZV8xLTEtMS0xLTIyNjY0_267a6da6-b165-4d5a-b7b5-06fc870c0717">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Y2QzN2M0YjUyOTAyNGUzMzkxMTQ3MDU1MGIyMjJiNmUvdGFibGVyYW5nZTpjZDM3YzRiNTI5MDI0ZTMzOTExNDcwNTUwYjIyMmI2ZV8xLTItMS0xLTIyNjY0_5de7a3c3-8194-4a61-9fea-89ad0acd1400">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzg2_2bb93e4d-685c-4d3b-8ad7-e79a6658a67a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzgx_6cb568aa-4189-47e7-a7b5-8fb8214abeca">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzg1_fa5c0e1b-4677-4273-bd7c-f4e83735ccca">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzg0_9c0148b4-f142-44cd-8438-39501b904d43">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc4_5ffa55d4-f3d5-43af-9253-05ad8f725605">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i86120acddb484cb5af4c2c93815fd32e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operation and Financial Condition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 28, 2022, we issu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ed a press release to report our financial results for the quarter ended December 31, 2021.  A copy of the press release is attached to this current report on Form&#160;8-K as Exhibit&#160;99.1.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i86120acddb484cb5af4c2c93815fd32e_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:13.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2022-0.htm">Press Release of Lexicon Pharmaceuticals, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2022-0.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2022-0.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressreleaseearnings2022-0.htm">bruary 28, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EX-104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i86120acddb484cb5af4c2c93815fd32e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:50.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseearnings2022-0.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idd8dd046fd1843248cd2581b6eed1b61_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Conference Call and Webcast at 8&#58;00 am Eastern Time</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">The Woodlands, Texas, February 28, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> - </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Lexicon Pharmaceuticals, Inc</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (Nasdaq&#58; LXRX) today reported financial results for the three months and full-year ended December 31, 2021 and provided an update on key milestones.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We remain focused on advancing sotagliflozin for the millions of people suffering from heart failure and living with type 2 diabetes on a daily basis. We announced today that we voluntarily withdrew the sotagliflozin NDA to correct a technical issue that we recently identified, and we plan to promptly resubmit early in the second quarter of 2022,&#8221; said Lonnel Coats, Lexicon&#8217;s chief executive officer. &#8220;In addition, we are looking forward to completing and announcing top-line results in the coming months from our two proof-of-concept Phase 2 studies of LX9211 in diabetic peripheral neuropathic pain and post-herpetic neuralgia.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Fourth Quarter Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sotagliflozin</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#242424;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">Lexicon submitted a New Drug Application (NDA) to the FDA at the end of the fourth quarter of 2021 seeking approval for the marketing and sale of sotagliflozin, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Today, Lexicon announced its voluntary withdrawal and planned near-term resubmission of the NDA to correct a technical issue with the submission recently identified by the company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">A new analysis evaluating the clinical benefit of sotagliflozin in heart failure and blood glucose control across the full range of kidney function was presented at the American Heart Association Scientific Sessions 2021.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Sotagliflozin significantly reduced total cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure, as well as decreased hemoglobin A1c, across the full range of kidney function studied, including individuals with moderate-to-severe chronic kidney disease.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LX9211</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.5pt">Patient enrollment continued in two ongoing Phase 2 clinical studies of LX9211&#58; RELIEF-DPN-1 for the treatment of diabetic peripheral neuropathic pain and RELIEF-PHN-1 for the treatment of post-herpetic neuralgia.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon anticipates completing recruitment this week for RELIEF-DPN-1 and expects top-line results for the study by the end of the second quarter of 2022.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Top-line results for RELIEF-PHN-1 are expected in the third quarter of 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Fourth Quarter and Full-Year 2021 Financial Highlights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2021 compared to the fourth quarter and full year of 2020.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Revenues&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Revenues were negligible for the fourth quarters of 2021 and 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Full-year revenues were negligible in 2021 as compared to $24.0 million for 2020, primarily due to the absence of product revenues in 2021 as a result of Lexicon&#8217;s sale of its XERMELO product and related assets to TerSera Therapeutics LLC during the third quarter of 2020.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research and Development (R&#38;D) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> R&#38;D expenses for the fourth quarter of 2021 increased to $16.5 million from $1.0 million for the corresponding period in 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The R&#38;D expense in the fourth quarter of 2020 reflected a reduction in external clinical development cost estimates primarily related to sotagliflozin R&#38;D expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Full-year R&#38;D expenses decreased to $55.0 million in 2021 from $153.6 million in 2020, primarily due to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">lower sotagliflozin clinical external research expenses, partially offset by higher LX9211 clinical external research expenses. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Selling, General and Administrative (SG&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> SG&#38;A expenses for the fourth quarter of 2021 increased to $8.8 million from $6.4 million for the corresponding period in 2020, primarily due to higher legal fees during the quarter.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Full-year SG&#38;A expenses for 2021 decreased to $32.3 million from $47.2 million, primarily due to lower salaries and benefits and marketing costs. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Gain on Sale of XERMELO&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A gain of $132.6 million was recognized during 2020 from the sale of XERMELO and related assets to TerSera in September 2020.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Net Income (Loss)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Net loss for the fourth quarter of 2021 was $25.6 million, or $0.17 per share, as compared to a net loss of $5.5 million, or $0.04 per share, in the corresponding period in 2020. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For the fourth quarter of 2021 and 2020, net loss included non-cash, stock-based compensation expense of $2.2 million and $2.7 million, respectively. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Net loss for the full-year was $87.8 million, or $0.60 per share, in 2021 as compared to a net loss of $58.6 million, or $0.53 per share, in 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">20. For the full years of 2021 and 2020, net loss included non-cash, stock-based compensation expense of $10.6 million and $13.3 million, respectively.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cash and Investments&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> As of December 31, 2021, Lexicon had $86.7 million in cash and investments, as compared to $152.3 million as of December 31, 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Conference Call and Webcast Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon management will hold a live conference call and webcast today at 8&#58;00 am ET &#47; 7&#58;00 am CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is 888-645-5785 (U.S.&#47;Canada) or 970-300-1531 (international). The conference ID for all callers is 8051406. The live webcast and replay may be accessed by visiting Lexicon&#8217;s website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.lexpharma.com&#47;investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. An archived version of the webcast will be available on the website for 14 days. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Lexicon Pharmaceuticals</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. Through its Genome5000&#8482; program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For additional information, please visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.lexpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Safe Harbor Statement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements,&#8221; including statements relating to Lexicon&#8217;s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon&#8217;s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management&#8217;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#8217;s ability to meet its capital requirements, successfully conduct preclinical </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#8217;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#8220;Risk Factors&#8221; in Lexicon&#8217;s annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idd8dd046fd1843248cd2581b6eed1b61_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Selected Financial Data</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ -</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,404</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative agreements</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,995</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (including finite-lived intangible</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;asset amortization)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $676, $1,223, $4,284 and $6,376, respectively</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,498</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,046</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,621</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $1,552, $1,457, $6,293 and $6,898, respectively</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,846</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,342</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,230</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss on buildings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,344</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,424</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,388</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,380</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on sale of XERMELO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,585</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss  from operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,330)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,458)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,090)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,800)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on debt extinguishments, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(802)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,544)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (25,611)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,495)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,758)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,574)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share, basic and diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.17)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.04)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.60)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ (0.53)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;common share, basic and diluted&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,897</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,359</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,652</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,841</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec. 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dec. 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash and investments&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$ 152,275</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Property and equipment, net&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;....</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,543</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total assets&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,909</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,788</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current debt&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,646</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Accumulated deficit&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;  </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,487,776)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,400,018)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total stockholders' equity&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;..</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,595</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,371</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idd8dd046fd1843248cd2581b6eed1b61_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">For Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Chas Schultz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Executive Director, Corporate Communications and Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Lexicon Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">(281) 863-3421</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">cschultz&#64;lexpharma.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrx-20220228.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:273b90fe-be65-4551-950d-6c0cc4735d9f,g:6d12946c-48d0-402f-a3e8-a90b7decbbc7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20220228" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20220228">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220228_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220228_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lexpharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lxrx-20220228_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:273b90fe-be65-4551-950d-6c0cc4735d9f,g:6d12946c-48d0-402f-a3e8-a90b7decbbc7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_17dea50a-bf53-4a3c-959d-0d453461f09c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_20a15dee-cdc7-4a4a-9fdf-cbc69ce11a0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_060998f0-acbd-44c4-a8ea-6ccbad2ea828_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_901d6220-86fa-446e-9860-780b97c49423_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c4e615aa-2a6b-4d00-a0e5-3558bd628ee8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a98b4975-bee8-4af5-a270-f1ac31fcb498_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3eaac7b8-26a0-4bae-a67f-67d93d8757b3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_52b48c3d-cdf6-4855-a8b7-0ae6091529fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_640e9e3b-af91-42ea-a9c9-3d815442e052_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b184fca9-6d91-4f8f-bca0-f7a7cc606c43_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f7507922-63ae-40bb-bf5d-68bea0680c30_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4e1cd5f5-1689-4d1d-800f-638f4c87bc33_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7551d47e-0ce7-4b0a-8347-e6ea083b9700_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d805f1b5-cb59-487b-aa0c-a2ff41d1cb39_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f7426aa7-0ff0-49e8-965d-ec0d8bffdef4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e8ba55ff-083a-45c8-8cae-7614ca4c4d19_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_560835eb-7355-4479-888c-a4cf6de34080_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3f8d9f52-4cea-4237-9e2f-3c14066072a3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2e4a8ea3-0155-467c-bfdb-68b6560f2184_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1a43d152-129c-48cd-b3a0-440ab0de2105_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_05fe8e86-d65b-4241-be37-9b0077e7d1ed_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a7d1de37-a0d2-4f75-881c-0c9361558a5e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lxrx-20220228_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:273b90fe-be65-4551-950d-6c0cc4735d9f,g:6d12946c-48d0-402f-a3e8-a90b7decbbc7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20220228.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ba1f7cd5-f83a-44fa-85cc-2b67ff23ffcc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_DocumentType_ba1f7cd5-f83a-44fa-85cc-2b67ff23ffcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_52d481d7-47f4-44d5-ad22-6adc378ba8ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_DocumentPeriodEndDate_52d481d7-47f4-44d5-ad22-6adc378ba8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9b08eed8-daff-40c2-b042-9301caecacf9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityRegistrantName_9b08eed8-daff-40c2-b042-9301caecacf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7d64bcff-048e-420d-9b06-51fa05c492da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7d64bcff-048e-420d-9b06-51fa05c492da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8cee4bc6-51d5-404a-a6ba-cef655a61c21" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityFileNumber_8cee4bc6-51d5-404a-a6ba-cef655a61c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8840223b-cfb0-4487-aebb-5f0f73db95ca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityTaxIdentificationNumber_8840223b-cfb0-4487-aebb-5f0f73db95ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_868dd26c-bfde-4683-a0d8-0a844c7d832e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityAddressAddressLine1_868dd26c-bfde-4683-a0d8-0a844c7d832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cb568142-b581-4720-904b-3e66cb2cf0b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityAddressCityOrTown_cb568142-b581-4720-904b-3e66cb2cf0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5e098e6d-390d-4c7f-bc40-9032b782b029" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityAddressStateOrProvince_5e098e6d-390d-4c7f-bc40-9032b782b029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6c13af78-1978-43ea-949a-0ee255aebb95" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityAddressPostalZipCode_6c13af78-1978-43ea-949a-0ee255aebb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_566d21c0-add5-477d-9665-132ad69dff0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_CityAreaCode_566d21c0-add5-477d-9665-132ad69dff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b7c5f423-b936-4ce6-a47e-f5f1283542c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_LocalPhoneNumber_b7c5f423-b936-4ce6-a47e-f5f1283542c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_755842cf-94bb-45cc-bc1b-d503e3620bb5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_Security12bTitle_755842cf-94bb-45cc-bc1b-d503e3620bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_24f2f881-1490-415d-bd1e-214f675bc49e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_TradingSymbol_24f2f881-1490-415d-bd1e-214f675bc49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e3e7df1c-02e8-429b-8dd6-f239d9f1f7ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_SecurityExchangeName_e3e7df1c-02e8-429b-8dd6-f239d9f1f7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_87a528c2-78a6-4cfe-af47-7dc50b77e490" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_WrittenCommunications_87a528c2-78a6-4cfe-af47-7dc50b77e490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c2a5658a-a3fc-40c1-bada-de2c95a1ac3d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_SolicitingMaterial_c2a5658a-a3fc-40c1-bada-de2c95a1ac3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6cf64c4a-b50a-49cc-b81c-e9a5fbc7d53a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_PreCommencementTenderOffer_6cf64c4a-b50a-49cc-b81c-e9a5fbc7d53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_155d5dcd-18fc-47cc-a150-5511b7b7c00d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_155d5dcd-18fc-47cc-a150-5511b7b7c00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d4445b49-1cb4-4076-a324-e5cf5f75182d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityEmergingGrowthCompany_d4445b49-1cb4-4076-a324-e5cf5f75182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fbada046-f5ec-4e71-ad20-b7fb3bd750a1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_EntityCentralIndexKey_fbada046-f5ec-4e71-ad20-b7fb3bd750a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_90c35a2d-2752-43c7-a0ee-9031f1f96f7f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2ccefbc6-8a32-4bcd-a2fa-96c65cfa0fde" xlink:to="loc_dei_AmendmentFlag_90c35a2d-2752-43c7-a0ee-9031f1f96f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139682497477720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 28,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>lxrx-20220228_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20220228.xsd" xlink:type="simple"/>
    <context id="i3c9b083932154f288268c27084adc8ac_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV80L2ZyYWc6ZDAxZTExMDk3YmEyNDZmYTg2ZTlhYzMyN2UzZThiOGEvdGFibGU6OThmMzU5YWM5NmIyNDMwNmJlZjRkMzRkZjZkZGFjNzEvdGFibGVyYW5nZTo5OGYzNTlhYzk2YjI0MzA2YmVmNGQzNGRmNmRkYWM3MV8wLTEtMS0xLTIyNjY0_4d263885-649a-45a5-b385-6ddc6673d1f9">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV80L2ZyYWc6ZDAxZTExMDk3YmEyNDZmYTg2ZTlhYzMyN2UzZThiOGEvdGFibGU6OThmMzU5YWM5NmIyNDMwNmJlZjRkMzRkZjZkZGFjNzEvdGFibGVyYW5nZTo5OGYzNTlhYzk2YjI0MzA2YmVmNGQzNGRmNmRkYWM3MV8xLTEtMS0xLTIyNjY0_1455cc72-9b68-47a3-ad3e-f18d2bd140b6">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc1_ad6cb52b-1c1a-4778-847a-18501610f667">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18yNjU_5542e1c1-5d92-45ab-893d-35e40be22ba5">2022-02-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc2_2df0d953-5afc-4ec0-a27b-d131b0f67545">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Yjc4MmIxYzRlNmY1NGFiYzhkYTMzN2YxNGNhOWY1MDgvdGFibGVyYW5nZTpiNzgyYjFjNGU2ZjU0YWJjOGRhMzM3ZjE0Y2E5ZjUwOF8wLTAtMS0xLTIyNjY0_77e41f9a-4ebb-4bec-9b3a-1eb5f6b188b8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Yjc4MmIxYzRlNmY1NGFiYzhkYTMzN2YxNGNhOWY1MDgvdGFibGVyYW5nZTpiNzgyYjFjNGU2ZjU0YWJjOGRhMzM3ZjE0Y2E5ZjUwOF8wLTEtMS0xLTIyNjY0_136cc656-0649-4acf-9e55-7a9675ccd568">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Yjc4MmIxYzRlNmY1NGFiYzhkYTMzN2YxNGNhOWY1MDgvdGFibGVyYW5nZTpiNzgyYjFjNGU2ZjU0YWJjOGRhMzM3ZjE0Y2E5ZjUwOF8wLTItMS0xLTIyNjY0_bb01bf2d-4e62-4813-92d7-936581e1fc95">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc3_7372ef37-cb2d-44d7-9741-3608359d3dbe">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc0_c4a04b16-4d73-4648-abb4-5448da6a8219">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc5_f87e9e8b-1704-417d-9039-1663b96fa3a1">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y180MjA_1bdd8d6f-795d-4a8d-ad98-275a1f43eefd">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y180Nzk_7331dc80-7e09-4345-a9fd-0bfd5aaeea5b">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzgw_6a468c11-d390-457c-b19d-38a3520341ef">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Y2QzN2M0YjUyOTAyNGUzMzkxMTQ3MDU1MGIyMjJiNmUvdGFibGVyYW5nZTpjZDM3YzRiNTI5MDI0ZTMzOTExNDcwNTUwYjIyMmI2ZV8xLTAtMS0xLTIyNjY0_74ab4cde-9b3d-49f8-8aa3-fb7d36827b13">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Y2QzN2M0YjUyOTAyNGUzMzkxMTQ3MDU1MGIyMjJiNmUvdGFibGVyYW5nZTpjZDM3YzRiNTI5MDI0ZTMzOTExNDcwNTUwYjIyMmI2ZV8xLTEtMS0xLTIyNjY0_267a6da6-b165-4d5a-b7b5-06fc870c0717">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGFibGU6Y2QzN2M0YjUyOTAyNGUzMzkxMTQ3MDU1MGIyMjJiNmUvdGFibGVyYW5nZTpjZDM3YzRiNTI5MDI0ZTMzOTExNDcwNTUwYjIyMmI2ZV8xLTItMS0xLTIyNjY0_5de7a3c3-8194-4a61-9fea-89ad0acd1400">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzg2_2bb93e4d-685c-4d3b-8ad7-e79a6658a67a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzgx_6cb568aa-4189-47e7-a7b5-8fb8214abeca">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzg1_fa5c0e1b-4677-4273-bd7c-f4e83735ccca">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzg0_9c0148b4-f142-44cd-8438-39501b904d43">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3c9b083932154f288268c27084adc8ac_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2MTIwYWNkZGI0ODRjYjVhZjRjMmM5MzgxNWZkMzJlL3NlYzo4NjEyMGFjZGRiNDg0Y2I1YWY0YzJjOTM4MTVmZDMyZV8xL2ZyYWc6NzY5YWJmYzQzZTgxNGIwODk2ZTE0NWI0ZjdjZGE2OGMvdGV4dHJlZ2lvbjo3NjlhYmZjNDNlODE0YjA4OTZlMTQ1YjRmN2NkYTY4Y18xNzc4_5ffa55d4-f3d5-43af-9253-05ad8f725605">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "<R7%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  G,EQ4WL*D$>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OITE!)71S43PI""XHWD(RNQMLFI",M/OVIG6WB^@#>,S,GV^^
M@>E,E"8D?$XA8B*'^6KR_9"EB1MV((H2()L#>IWKDAA*<Q>2UU2>:0]1FP^]
M1Q!-<PT>25M-&F9@%5<B4YTUTB34%-();\V*CY^I7V#6 /;H<: ,O.; U#PQ
M'J>^@PM@AA$FG[\+:%?B4OT3NW2 G9)3=FMJ',=Z;)=<V8'#V]/CR[)NY89,
M>C!8?F4GZ1AQP\Z37]N[^^T#4Z(1HFI$)6ZWG$M^(WG[/KO^\+L(^V#=SOUC
MX[.@ZN#77:@O4$L#!!0    ( "<R7%297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
M-5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K
M!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1U
MW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@
M;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ )S)<5&60>9(9
M 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL
M6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4
M'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I
M>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY
M'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?K
MT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;
M@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"
M% ,4    "  G,EQ4!T%-8H$   "Q    $               @ $     9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "<R7%3>PJ01[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "<R
M7%297)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ )S)<5 9"IC]#!   21   !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "<R
M7%2?H!OPL0(  .(,   -              "  84,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ )S)<5)>*NQS     $P(   L              ( !80\
M %]R96QS+RYR96QS4$L! A0#%     @ )S)<5*K$(A8S 0  (@(   \
M         ( !2A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "<R7%0D
M'INBK0   /@!   :              "  :H1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( "<R7%1ED'F2&0$  ,\#   3
M      "  8\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' -D3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20220228.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrx-20220228.htm">lxrx-20220228.htm</File>
    <File>lxrx-20220228.xsd</File>
    <File>lxrx-20220228_lab.xml</File>
    <File>lxrx-20220228_pre.xml</File>
    <File>pressreleaseearnings2022-0.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20220228.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "lxrx-20220228.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20220228_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20220228_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20220228.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20220228",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220228.htm",
      "contextRef": "i3c9b083932154f288268c27084adc8ac_D20210730-20210730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.lexpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220228.htm",
      "contextRef": "i3c9b083932154f288268c27084adc8ac_D20210730-20210730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001062822-22-000002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-22-000002-xbrl.zip
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M&+9US<::8RC$=12=Z=I/+H<:Q_J&MY8<%CZG$,:BU[K":-X2O1>,H^L1$]2
MT'F*/!E3PU0OT+C'Y3;R6_%N(+;%(""EP.8<G2?Q..L)H@Y%#$Q3Q+@/0\@S
MEKD#KQAW'->_/J6OH0U!1FL+2=]]WCJ0QS.'XGBFV*>>+XWJ8G7-L__74,7J
M7'>\ ;=\C[5:4)PO6*2NK2 \NJ?LO7K=G6_&FZ-[(+'=S9%]5]NW=E3J9X8/
M#I3!0&UKS,"Z1GWLJ(:&%8,RV[=4PU2,[ZKM>ZJL%Y2"NO\-)20VMMRIT8*E
MY%T/])7,G(*^BF)I T8IEZT T2)'*.Y!#>2^C_Q>.<%]<JQP*@:7=^4*$8P
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M]Z$_$;16OS<6E5;R7_F6/PV^_?]02P,$%     @ )S)<5"EG09]O @  ?0<
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M"H;KM?]^LH).L-_NU>@W4$L#!!0    ( "<R7%2YU!\-/0H  *)=   5
M;'AR>"TR,#(R,#(R.%]L86(N>&ULU9Q=;]LX%H;O^RNXGIM=8%A3$B5119M!
M-],NBLVT19.B@UTL#'XF0FTID)4F^?=+R78BV9)-2K:JN4D<FSY\SVL]AQ]B
M_/JWA\4<_)#9,DZ3-Q/G)9H F?!4Q,GUF\G7J_>03'X[>_'B]=\@_/.?7R[
M[RF_6\@D!^>9I+D4X#[.;\ W(9??@<K2!?B69M_C'Q3"L_)-Y^GM8Q9?W^3
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M?C('YF-(/N4U ?-B4$^S[4Q3WIKI,QQ++;),<RGYR^OTQU2_1:?KHN(!+!Y
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MC#@;+ G ?:XLLUZ,<<O\L>5A-$RX,[FCF*^,PEF"CF.H//3/?W2/$:4/$?W
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MU&-TL.\9'<; A#N8+Y=PM+E_NW@DWBD>.'QS^T/WTCV:?_CF_U!+ P04
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MX0#\D2L(<99FL7-,%.4AN11QS"(PSF@""SI;Z=C":1XK$O0XZQ#VG06PYN]
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M@=["5.3R\@0&)G,O>9:NF+$R\VF9R"8!NTM'WH[TR_D=F\HO&:E2DS9B%X\
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M<G@M,C R,C R,C@N:'1M4$L! A0#%     @ )S)<5"EG09]O @  ?0<  !$
M             ( !'A0  &QX<G@M,C R,C R,C@N>'-D4$L! A0#%     @
M)S)<5+G4'PT]"@  HET  !4              ( !O!8  &QX<G@M,C R,C R
M,CA?;&%B+GAM;%!+ 0(4 Q0    ( "<R7%3S;6BCK08  &@Q   5
M      "  2PA  !L>')X+3(P,C(P,C(X7W!R92YX;6Q02P$"% ,4    "  G
M,EQ4B'>L1AD9  !(!P$ '@              @ $,*   <')E<W-R96QE87-E
H96%R;FEN9W,R,#(R+3 N:'1M4$L%!@     %  4 4 $  &%!      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
